Surgery Partners (SGRY) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual meeting scheduled for June 5, 2026, to be held virtually at 10:00 a.m. CDT.
Proxy materials are available online, with options for electronic or paper delivery upon request.
Voting matters and shareholder proposals
Election of three Class II directors: Devin O'Reilly, Brent Turner, and Laura L. Forese, M.D.
Advisory vote on executive compensation for named executive officers.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Board recommends voting FOR all nominees and proposals.
Board of directors and corporate governance
Board of Directors nominates three individuals for election as Class II directors.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Surgery Partners
- Q1 2026 revenue rose 4.5% to $810.9M; net loss narrowed and guidance reaffirmed.SGRY
Q1 20265 May 2026 - Annual meeting to vote on directors, executive pay, and auditor, with focus on governance and risk.SGRYProxy filing23 Apr 2026
- Payer mix shifts and cost actions drive a conservative outlook and portfolio optimization.SGRYBarclays 28th Annual Global Healthcare Conference10 Mar 2026
- 2025 margin pressure and net loss shape a cautious 2026 outlook with $530M EBITDA guidance.SGRYQ4 20253 Mar 2026
- Q2 revenue up 14.2%, Adjusted EBITDA up 18.1%, and 2024 guidance raised on strong growth.SGRYQ2 20242 Feb 2026
- Q3 revenue and EBITDA grew double digits, led by high acuity cases and acquisitions.SGRYQ3 202415 Jan 2026
- 2024 revenue up 13.5% and Adjusted EBITDA up 16%, with strong 2025 growth outlook.SGRYQ4 202415 Dec 2025
- Shareholders will vote on directors, executive pay, a new incentive plan, and auditor ratification.SGRYProxy Filing2 Dec 2025
- Virtual annual meeting on June 6, 2025, with board-backed votes on directors, pay, plan, and auditor.SGRYProxy Filing2 Dec 2025